Mahfouz El Shahawy

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Jennifer G. Robinson, Michel Farnier, Michel Krempf et al. · New England Journal of Medicine · 2015 · 2.3K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

The Changing Landscape for Stroke Prevention in AF

Menno V. Huisman, Kenneth J. Rothman, Miney Paquette et al. · Journal of the American College of Cardiology · 2017 · 281 citations · Full text

Medicine, Cardiology, Pharmacotherapy +10

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17